Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia
Platelet transfusion refractoriness (PTR) is an intractable clinical issue with increasing risks of bleeding and mortality in patients with acute myeloid leukemia (AML) after receiving platelet transfusion. In the present manuscript, patients with CBF ‐AML and patients who further had better minimal residual disease (MRD) reduction (≥3‐log) after induction chemotherapy had higher tendency to develop HLA‐I antibodies and PTR. Moreover, HLA‐B was the most frequently identified serum epitope in PTR patients. AbstractPlatelet transfusion is important in the prevention and treatment of bleeding in patients with acute myeloid leukemia (AML) after receiving intensive chemotherapy. However, platelet transfusion refractoriness (PTR) is an intractable clinical issue occurred in these patients. And its clinical and immunological features remain largely unknown. The potential causes and clinical features of PTR were retrospectively analyzed in 560 patients who were diagnosed as de novo AML in Tongji Hospital from June 2012 through June 2018. A high ‐throughput antibody screening for the detection of human leukocyte antigen (HLA) and its serotypes was performed in 133 newly diagnosed AML patients. PTR occurred in 11.8% of the de novo AML patients. The median age for patients with PTR was 46 years (range, 15‐70). It frequently manifested in female patients and in patients with splenomegaly, M4 subtype,c ‐Kit gene mutation, and rearrangements ofRUNX1 ‐RUNX1T1 orCBFB ‐MY...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Xuelian Hu,
Haodong Cai,
Lu Zheng,
Yi Luo,
Jing Zhou,
Yan Hui,
Zhenyu Dai,
Haolong Lin,
Dengju Li,
Yi Xiao,
Liang Huang,
Jianfeng Zhou Tags: ORIGINAL RESEARCH Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Allergy & Immunology | Bleeding | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Hospitals | Leukemia